9.00
price up icon2.04%   0.18
after-market Handel nachbörslich: 9.44 0.44 +4.89%
loading
Schlusskurs vom Vortag:
$8.82
Offen:
$8.8
24-Stunden-Volumen:
1.79M
Relative Volume:
0.85
Marktkapitalisierung:
$937.92M
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-3.0405
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
+1.12%
1M Leistung:
-18.03%
6M Leistung:
-36.08%
1J Leistung:
-56.44%
1-Tages-Spanne:
Value
$8.77
$9.495
1-Wochen-Bereich:
Value
$8.74
$9.561
52-Wochen-Spanne:
Value
$8.58
$25.07

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name
Firmenname
Syndax Pharmaceuticals Inc
Name
Telefon
781-419-1400
Name
Adresse
730 THIRD AVENUE, NEW YORK, MA
Name
Mitarbeiter
184
Name
Twitter
@syndax
Name
Nächster Verdiensttermin
2025-03-03
Name
Neueste SEC-Einreichungen
Name
SNDX's Discussions on Twitter

Vergleichen Sie SNDX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SNDX
Syndax Pharmaceuticals Inc
9.00 937.92M 139.71M -209.36M -160.60M -2.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-24 Eingeleitet UBS Buy
2024-06-28 Eingeleitet Jefferies Buy
2024-01-31 Herabstufung Scotiabank Sector Outperform → Sector Perform
2023-12-22 Eingeleitet Mizuho Buy
2023-10-25 Eingeleitet BofA Securities Buy
2023-10-11 Eingeleitet Goldman Buy
2023-07-27 Eingeleitet Scotiabank Sector Outperform
2023-07-11 Eingeleitet Guggenheim Buy
2023-04-17 Fortgesetzt BTIG Research Buy
2023-01-31 Eingeleitet Stifel Buy
2023-01-03 Eingeleitet JP Morgan Overweight
2022-07-28 Fortgesetzt B. Riley Securities Buy
2022-04-11 Eingeleitet H.C. Wainwright Buy
2022-02-15 Eingeleitet Goldman Buy
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-05-25 Eingeleitet Citigroup Buy
2021-02-18 Eingeleitet B. Riley Securities Buy
2020-12-03 Eingeleitet Stifel Buy
2020-05-22 Hochstufung Citigroup Neutral → Buy
2020-05-22 Herabstufung H.C. Wainwright Buy → Neutral
2020-05-18 Herabstufung Citigroup Buy → Neutral
2020-05-11 Bestätigt H.C. Wainwright Buy
2020-03-04 Eingeleitet Barclays Overweight
2020-01-13 Bestätigt H.C. Wainwright Buy
2019-03-08 Bestätigt H.C. Wainwright Buy
2019-01-04 Eingeleitet Robert W. Baird Outperform
2018-01-05 Eingeleitet B. Riley FBR, Inc. Buy
2017-03-16 Eingeleitet FBR & Co. Outperform
2017-03-02 Eingeleitet Instinet Buy
2016-10-07 Eingeleitet Guggenheim Buy
2016-03-28 Eingeleitet Citigroup Buy
2016-03-28 Eingeleitet JMP Securities Mkt Outperform
2016-03-28 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten

pulisher
Jun 17, 2025

Learn to Evaluate (SNDX) using the Charts - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 17, 2025

Syndax Pharmaceuticals’ SWOT analysis: revuforj launch boosts aml treatment stock - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Syndax Pharmaceuticals' SWOT analysis: revuforj launch boosts aml treatment stock - Investing.com

Jun 17, 2025
pulisher
Jun 16, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7%What's Next? - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Assenagon Asset Management S.A. Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Jun 16, 2025
pulisher
Jun 13, 2025

Syndax reports publication of revumenib data from BEAT AML trial - Yahoo Finance

Jun 13, 2025
pulisher
Jun 13, 2025

SNDX Trial Data Shows Promising Results in AML Treatment | SNDX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Syndax Presents New Revuforj® (revumenib) Data in - GlobeNewswire

Jun 13, 2025
pulisher
Jun 12, 2025

Syndax Announces Publication of Revumenib Data from the BEAT AML - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 - The Manila Times

Jun 12, 2025
pulisher
Jun 12, 2025

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 | SNDX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Syndax Announces Publication of Revumenib Data from the - GlobeNewswire

Jun 12, 2025
pulisher
Jun 12, 2025

Clinical Trial: New AML Drug Achieves 100% MRD Negativity, Doubles Survival vs Standard Care - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of ... - Eagle-Tribune

Jun 12, 2025
pulisher
Jun 12, 2025

Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj - The Pharma Letter

Jun 12, 2025
pulisher
Jun 12, 2025

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refra - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

SNDX: New Data Revealed from Syndax's AUGMENT-101 Trial | SNDX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 | SNDX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 - The Manila Times

Jun 12, 2025
pulisher
Jun 11, 2025

Syndax Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Profitability - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 32,653 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Jun 10, 2025
pulisher
Jun 09, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Ameriprise Financial Inc. - MarketBeat

Jun 09, 2025
pulisher
Jun 07, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

Syndax Pharmaceuticals at Jefferies Conference: Strategic Growth and Expansion By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Li - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | SNDX Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jun 05, 2025
pulisher
Jun 05, 2025

Ameriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Bank of America Corp DE Sells 546,799 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Long Term Trading Analysis for (SNDX) - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 04, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Nuveen Asset Management LLC - MarketBeat

Jun 04, 2025
pulisher
Jun 03, 2025

Voloridge Investment Management LLC Acquires Shares of 79,071 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Wellington Management Group LLP Has $55.98 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 4.9% HigherShould You Buy? - MarketBeat

Jun 03, 2025
pulisher
Jun 02, 2025

84,998 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Purchased by Polar Asset Management Partners Inc. - MarketBeat

Jun 02, 2025
pulisher
Jun 01, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DE - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Millennium Management LLC Lowers Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

May 31, 2025
pulisher
May 31, 2025

Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $35.91 - MarketBeat

May 31, 2025
pulisher
May 31, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LP - MarketBeat

May 31, 2025
pulisher
May 29, 2025

Syndax Announces Participation in June Investor Conferences | SN - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Syndax Announces Participation in June Investor Conferences - The Manila Times

May 29, 2025

Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Syndax Pharmaceuticals Inc-Aktie (SNDX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Huber Martin H. Jr.
Director
May 19 '25
Buy
8.99
5,000
44,950
79,000
Katkin Keith
Director
May 19 '25
Buy
9.11
10,000
91,120
100,000
Metzger Michael A
Chief Executive Officer
Mar 14 '25
Option Exercise
7.20
6,074
43,733
306,195
Metzger Michael A
Chief Executive Officer
Mar 04 '25
Option Exercise
7.20
7,814
56,261
307,935
Metzger Michael A
Chief Executive Officer
Mar 04 '25
Sale
15.05
7,814
117,564
300,121
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):